Biodesix announces publication of the oracle clinical utility study with the primary endpoint demonstrating that the nodify xl2® test reduced unnecessary invasive procedures on benign lung nodules

Boulder, colo.--(business wire)---- $bdsx #patientsfirst--biodesix, inc. (nasdaq: bdsx), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that the prospective, real-world oracle study (an observational registry study to evaluate the performance of the nodify xl2® test [nct03766958]) achieved the primary endpoint of a statistically significant change in the proportion of benign lung nodules managed by nodify xl2® experiencing invasive procedures. the data was published in.
BDSX Ratings Summary
BDSX Quant Ranking